Literature DB >> 30129772

Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol.

Satish K Garg1,2, Anne L Peters3, John B Buse4, Thomas Danne5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30129772     DOI： 10.1089/dia.2018.0246

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN： 1520-9156            Impact factor:   6.118


× No keyword cloud information.
  22 in total

1.  Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.

Authors:  Bruce A Perkins; Julio Rosenstock; Jay S Skyler; Lori M Laffel; David Z Cherney; Chantal Mathieu; Christianne Pang; Richard Wood; Ona Kinduryte; Jyothis T George; Jan Marquard; Nima Soleymanlou
Journal:  Diabetes Care       Date:  2019-06-08       Impact factor: 19.112

2.  Empagliflozin as an adjunctive therapy for type 1 diabetes.

Authors:  Richard J MacIsaac; Melissa H Lee; Sybil A McAuley; Glenn M Ward; David N O'Neal
Journal:  Ann Transl Med       Date:  2018-12

Review 3.  Pharmacologic treatment options for type 1 diabetes: what's new?

Authors:  Laura M Nally; Jennifer L Sherr; Michelle A Van Name; Anisha D Patel; William V Tamborlane
Journal:  Expert Rev Clin Pharmacol       Date:  2019-05       Impact factor: 5.045

Review 4.  SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.

Authors:  Hongyan Liu; Vikas S Sridhar; Bruce A Perkins; Julio Rosenstock; David Z I Cherney
Journal:  Curr Diab Rep       Date:  2022-05-28       Impact factor: 4.810

Review 5.  Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy.

Authors:  Melissa-Rosina Pasqua; Michael A Tsoukas; Ahmad Haidar
Journal:  J Diabetes Sci Technol       Date:  2021-09-24

6.  Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy.

Authors:  Stephan Siebel; Alfonso Galderisi; Neha S Patel; Lori R Carria; William V Tamborlane; Jennifer L Sherr
Journal:  Diabetes Technol Ther       Date:  2019-01-28       Impact factor: 6.118

7.  Therapeutic Inertia in Pediatric Diabetes: Challenges to and Strategies for Overcoming Acceptance of the Status Quo.

Authors:  Sarah D Corathers; Daniel J DeSalvo
Journal:  Diabetes Spectr       Date:  2020-02

8.  Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor.

Authors:  Rhea Teng; Martin Kurian; Kelly L Close; John B Buse; Anne L Peters; Charles M Alexander
Journal:  Diabetes Spectr       Date:  2021-01

9.  Continuous Ketone Monitoring Consensus Report 2021.

Authors:  Kevin T Nguyen; Nicole Y Xu; Jennifer Y Zhang; Trisha Shang; Ananda Basu; Richard M Bergenstal; Kristin Castorino; Kong Y Chen; David Kerr; Suneil K Koliwad; Lori M Laffel; Nestoras Mathioudakis; L Kurt Midyett; Joshua D Miller; James H Nichols; Francisco J Pasquel; Priya Prahalad; Mark R Prausnitz; Jane Jeffrie Seley; Jennifer L Sherr; Elias K Spanakis; Guillermo E Umpierrez; Amisha Wallia; David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2021-10-04

10.  Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.

Authors:  Bruce W Bode; Eda Cengiz; R Paul Wadwa; Phillip Banks; Thomas Danne; Jake A Kushner; Darren K McGuire; Anne L Peters; Paul Strumph; Sangeeta Sawhney
Journal:  Diabetes Technol Ther       Date:  2021-01       Impact factor: 6.118
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.